#USA #Duluth #Bridge to Life #VitaSmart™ #Hope

A Game-Changer in Organ Preservation

In a groundbreaking study published in the Journal of the American Medical Association (JAMA) Surgery, researchers have validated the VitaSmart™ HOPE perfusion system by Bridge to Life as a superior organ preservation technology. This study not only showcases the efficacy of this innovative system but also opens new channels for organ transplantation, especially in a market currently burdened by a shortage of donor organs.

The Bridge to HOPE clinical trial is pivotal in demonstrating the benefits of hypothermic oxygenated perfusion (HOPE) for liver transplants. Conducted across 15 transplant centers in the United States, the study included 219 recipients and aimed to explore the clinical impacts of HOPE in use with high-risk donor organs, primarily those categorized under expanded criteria, including those received after brain death (DBD) and circulatory death (DCD).

The results evident from the study reveal a marked increase in the utilization of marginal donor organs, significantly boosting the availability of transplants for the over 100,000 patients on waiting lists in the U.S. The findings indicated that the HOPE perfusion method could successfully broaden the use of these organs, offering a better prognosis post-transplantation.

Study Design and Outcomes

The Bridge to HOPE study was meticulously designed with a blinded central evaluation of complications which enabled statistical superiority for the VitaSmart arm. The study conclusively ended early due to the outstanding results revealed by the application of the VitaSmart HOPE system.

What's more, the recently acquired De-novo approval from the U.S. Food and Drug Administration (FDA) for this perfusion system marks a revolutionary step in the regulatory landscape for organ conservation practices. This new classification underscores the growing acceptance and validation within the medical community for advanced preservation technologies.

Implications for Transplantation Community

Mauricio Carvalho, Vice President of Medical Affairs at Bridge to Life, emphasized the significance of these findings, stating, “The results clearly demonstrate the opportunities VitaSmart presents for the transplantation community. This study illustrates that portal-venous HOPE serves as a straightforward, safe, and effective preservation strategy with considerable clinical advantages, providing a feasible alternative amid the limitations of current perfusion infrastructure in the U.S.”

Additionally, the approach adopted through the VitaSmart system seems to reduce liver-related complications associated with transplantation, further establishing its potential impact on patient outcomes.

The anticipation surrounding the publication of this study has been echoed by Don Webber, the CEO of Bridge to Life, who mentioned that despite the clear clinical validation of such advanced technologies, the adoption has been sluggish due to operational complexities and cost issues that have historically undermined broader implementation.

“Bridge to Life is committed to resolving these limitations with a seamless solution that fits well into transplantation workflows, facilitating scalable adoption,” he noted, expressing hope that the understanding of this novel organ preservation technology will increase among transplant and surgical communities, as well as the many patients waiting for transplants.

About Bridge to Life Ltd

Bridge to Life Ltd is a frontrunner in organ preservation, providing top-tier products including the VitaSmart™ Hypothermic Oxygenated Perfusion System, Belzer UW®, and EasiSlush®. With an emphasis on innovation, quality, and accessibility, the company collaborates closely with leading transplant hospitals and organ procurement organizations worldwide.

As medical advancements continue to evolve, the validation of the VitaSmart system marks a pivotal moment in the field of organ transplantation, heralding a future where more lives can be saved through improved organ preservation techniques.